08/09/2026
Ozempic and drinking is having a moment, and most of the coverage is getting one number wrong.
The headline you have probably seen is that semaglutide cuts heavy drinking by 41%. That number is real, but it is only half the sentence. In the Lancet trial published this May, heavy drinking days fell 41.1 percentage points in the semaglutide group. They also fell 26.4 points in the placebo group. The difference the drug actually added was 13.7 points.
That is still a meaningful effect, and the research is genuinely promising. But the placebo group is the part I keep thinking about. Those people got a saline injection, some therapy, and somebody paying attention to their drinking every few weeks. They cut their heavy drinking days by more than a quarter.
Structure and support do a lot of the work, whatever is in the syringe.
Meanwhile there is a medication already approved in Canada for exactly this, backed by 118 trials and roughly 21,000 people, that costs about $2.81 a tablet and is a general benefit on the Ontario Drug Benefit formulary.
Most people have never been offered it.
Semaglutide does cut heavy drinking in trials, but no GLP-1 is approved in Canada for alcohol. Here is the honest evidence and what Ontarians can get now.